Standard Review For Delcath's Liver Treatment
The Food and Drug Administration accepted Delcath Systems Inc.'s (Nasdaq: DCTH) liver cancer treatment for standard review rather than priority review sending the stock price tumbling 39 cents to close at $1.70.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here